MLC Medical LLC is pleased to announce major strategic collaborations with two prominent Turkish pharmaceutical manufacturers, Aroma İlaç and Polifarma İlaç. Both companies are recognized for their high manufacturing standards and specialized production of sterile hospital injectables, parenteral solutions, and acute-care medications.

Through these combined partnerships, MLC Medical is significantly expanding its portfolio with the market registration of 24 essential therapies across critical therapeutic categories in Georgia:

• Anesthesia, Sedation & Neuromuscular Blockade: Sevones® (Sevoflurane), İsofluran-PF (Isoflurane), Dekstomid (Dexmedetomidine), and Muscobloc (Rocuronium Bromide)

• Cardiovascular & Hemodynamic Support: Mekard (Dobutamine), Simendan® (Levosimendan), and Esmobloc (Esmolol Hydrochloride)

• Antithrombotic & Anticoagulation Therapy: Venaperta (Enoxaparin Sodium) and Poliparin (Heparin Sodium)

• Broad-Spectrum Anti-Infectives: Polinoksid (Linezolid), POL-MOXI (Moxifloxacin), Levoxipolin (Levofloxacin), Polgyl (Metronidazole), Tygepol (Tigecycline), Teikopol® (Teicoplanin), and Vorikandin (Voriconazole)

• Critical Care, Fluid Therapy & Specialty Injectables: Polifleks 3% (Hypertonic Sodium Chloride), Cortipol® (Methylprednisolone), Hepalornitin® (L-Ornithine-L-Aspartate), Levetam (Levetiracetam), and Zygosis® (Pantoprazole)

These additions directly address the everyday clinical demands of intensive care units, operating rooms, emergency departments, and inpatient wards throughout Georgia. Securing reliable, European-standard sterile lines reinforces hospital supply stability and equips healthcare providers with proven therapeutic solutions.

MLC Medical looks forward to productive long-term collaborations with both Aroma İlaç and Polifarma, continuing our commitment to supplying Georgia’s medical sector with high-quality, dependable pharmaceuticals.